Meta Platforms
META
Coinbase
COIN
Amazon
AMZN
Apple
AAPL
Oracle
ORCL
US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 1.710
- +0.340+24.82%
Close Dec 3 16:00 ET
- 1.680
- -0.030-1.75%
Post 20:01 ET
197.01MMarket Cap-19000P/E (TTM)
2.430High1.670Low115.07MVolume2.040Open1.370Pre Close232.00MTurnover111.39%Turnover RatioLossP/E (Static)115.21MShares3.70052wk High-2.24P/B176.65MFloat Cap0.66052wk Low--Dividend TTM103.30MShs Float38.100Historical High--Div YieldTTM55.47%Amplitude0.660Historical Low2.016Avg Price1Lot Size
About Coherus BioSciences Company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Company Profile
SymbolCHRS
Company NameCoherus BioSciences
Listing DateNov 6, 2014
Issue Price13.50
Founded2010
CEOMr. Dennis M. Lanfear
MarketNASDAQ
Employees306
Fiscal Year Ends12-31
Address333 Twin Dolphin Drive,Suite 600
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-649-3530
Websitehttp://www.coherus.com
Company Executives
- Name
- Position
- Salary
- Dennis M. Lanfear
- President, Chief Executive Officer and Chairman of the Board
- 5.90M
- Paul Reider
- Chief Commercial Officer
- 1.93M
- Bryan J. McMichael
- Chief Financial Officer and Principal Accounting Officer
- 1.07M
- Rita A. Karachun
- Director
- --
- Georgia L. Erbez
- Director
- --
- Dr. Michael Ryan, Pharm.D.
- Director
- 173.61K
- Mats L. Wahlstrom
- Lead Independent Director
- 228.69K
- Dr. Lee N. Newcomer, M.D.
- Independent Director
- 186.19K
- Kimberly J. Commins-Tzoumakas
- Independent Director
- 193.69K
- Dr. Jill O’Donnell-Tormey
- Independent Director
- 183.69K
- Mark D. Stolper
- Independent Director
- 198.69K
- Charles Newton
- Independent Director
- 188.69K
- Ali J. Satvat
- Independent Director
- 65.00K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
